- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT07164443
- Juicio original
Un estudio de Pasritamig versus placebo en cáncer de próstata resistente a la castración metastásica de línea tardía (MCRPC) (KLK2-comPAS)
Un estudio de fase 3 aleatorizado, doble ciego, controlado con placebo de Pasritamig (JNJ-78278343), un agente redirigido de células T que se dirige a Kallikrein 2 humano, + mejor atención versus mejor atención de apoyo para la cuidados de cáncer de cáncer de castración metastásica metastásica
The purpose of this study is to evaluate the overall survival (length of time from the start of study to date of death from any cause) for pasritamig (JNJ-78278343) in Part 1 in combination with best supportive care (BSC) and in Part 2 with JNJ-87189401+BSC as compared to placebo with BSC in participants with metastatic castration-resistant prostate cancer (mCRPC; a stage of cancer that has spread beyond the prostate gland and is no longer responding to hormone therapies).
Descripción general del estudio
Estado
Intervención / Tratamiento
Tipo de estudio
Inscripción (Estimado)
Fase
- Fase 3
Contactos y Ubicaciones
Estudio Contacto
- Nombre: Study Contact
- Número de teléfono: 844-434-4210
- Correo electrónico: Participate-In-This-Study1@its.jnj.com
Ubicaciones de estudio
-
-
-
Braunschweig, Alemania, 38126 DE
- Reclutamiento
- Staedtisches Klinikum Braunschweig
-
Duisburg, Alemania, 47169
- Reclutamiento
- Urologicum Duisburg
-
Düsseldorf, Alemania, 40225
- Reclutamiento
- Universitaetsklinikum Duesseldorf
-
Essen, Alemania, 45147
- Reclutamiento
- Universitaetsklinikum Essen
-
Frankfurt am Main, Alemania, 60488
- Reclutamiento
- Krankenhaus NorthWest
-
Hamburg, Alemania, 20246
- Reclutamiento
- Martini-Klinik am UKE GmbH
-
Heidelberg, Alemania, 69120
- Reclutamiento
- Universitaetsklinikum Heidelberg Nationales Centrum fuer Tumorerkrankungen
-
München, Alemania, 81675
- Reclutamiento
- Klinikum rechts der Isar der TU Muenchen
-
Münster, Alemania, 48149
- Reclutamiento
- Universitaetsklinikum Muenster
-
Nuremberg, Alemania, 90419
- Reclutamiento
- Klinikum Nuernberg Nord
-
Nürtingen, Alemania, 72622
- Reclutamiento
- Studienpraxis Urologie Nurtingen
-
-
-
-
-
Heidelberg, Australia, 3084
- Reclutamiento
- Warringal Private Hospital
-
Kurralta Park, Australia, 5037
- Reclutamiento
- ICON Cancer Care
-
Melbourne, Australia, 3000
- Reclutamiento
- Peter MacCallum Cancer Centre
-
Murdoch, Australia, 6150
- Reclutamiento
- Fiona Stanley Hospital
-
Woolloongabba, Australia, 4102
- Reclutamiento
- Princess Alexandra Hospital
-
-
-
-
-
Florianópolis, Brasil, 88020 210
- Reclutamiento
- Grupo ELORA Centro de Pesquisa e Ensino em Saude de Santa Catarina
-
Joinville, Brasil, 89201 260
- Reclutamiento
- Instituto Joinvilense de Hematologia e Oncologia Ltda Centro de Hematologia e Oncologia
-
Natal, Brasil, 59062 000
- Reclutamiento
- Liga Norte Riograndense Contra O Cancer
-
Porto Alegre, Brasil, 90035-001
- Reclutamiento
- Hospital Moinhos de Vento
-
São Paulo, Brasil, 01509 900
- Reclutamiento
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
-
-
-
-
Bruges, Bélgica, 8000
- Reclutamiento
- AZ Sint-Jan
-
Brussels, Bélgica, 1200
- Reclutamiento
- Cliniques Universitaires Saint Luc
-
Ghent, Bélgica, 9000
- Reclutamiento
- Ghent University Hospital
-
Ghent, Bélgica, 9000
- Reclutamiento
- AZ Maria Middelares
-
Kortrijk, Bélgica, 8500
- Reclutamiento
- Az Groeninge
-
La Louvière, Bélgica, 7100
- Reclutamiento
- Chu Helora Hospital La Louviere Site Jolimont
-
Liège, Bélgica, 4000
- Reclutamiento
- CHC MontLegia
-
Ottignies, Bélgica, 1340
- Reclutamiento
- Clinique Saint Pierre
-
Wilrijk, Bélgica, 2610
- Reclutamiento
- ZAS Augustinus
-
-
-
-
Alberta
-
Calgary, Alberta, Canadá, T2N 5G2
- Reclutamiento
- Arthur J E Child Comprehensive Cancer Centre
-
-
British Columbia
-
Vancouver, British Columbia, Canadá, V5Z 4E6
- Reclutamiento
- BC Cancer Vancouver
-
-
Ontario
-
Oshawa, Ontario, Canadá, L1G2B9
- Reclutamiento
- Lakeridge Health
-
Toronto, Ontario, Canadá, M4N 3M5
- Reclutamiento
- Sunnybrook Health Sciences Center
-
Toronto, Ontario, Canadá, M5G 2C1
- Reclutamiento
- Princess Margaret Hospital
-
-
Quebec
-
Québec, Quebec, Canadá, G1J 1Z4
- Reclutamiento
- CHU de Quebec Universite Laval
-
-
-
-
-
Daejeon, Corea del Sur, 35015
- Reclutamiento
- Chungnam National University Hospital
-
Goyang-si, Corea del Sur, 10408
- Reclutamiento
- National Cancer Center
-
Hwasungun, Corea del Sur, 58128
- Reclutamiento
- Chonnam National University Hwasun Hospital
-
Seoul, Corea del Sur, 05505
- Reclutamiento
- Asan Medical Center
-
Seoul, Corea del Sur, 06351
- Reclutamiento
- Samsung Medical Center
-
Seoul, Corea del Sur, 03722
- Reclutamiento
- Severance Hospital Yonsei University Health System
-
Seoul, Corea del Sur, 06591
- Reclutamiento
- The Catholic University of Korea Seoul St Marys Hospital
-
-
-
-
-
Barcelona, España, 08035
- Reclutamiento
- Hosp Univ Vall D Hebron
-
Jerez de la Frontera, España, 11407
- Terminado
- Hosp. de Jerez de La Frontera
-
Madrid, España, 28034
- Reclutamiento
- Hosp. Univ. Ramon Y Cajal
-
Madrid, España, 28041
- Reclutamiento
- Hosp. Univ. 12 de Octubre
-
Málaga, España, 29010
- Reclutamiento
- Hosp Virgen de La Victoria
-
-
-
-
California
-
La Jolla, California, Estados Unidos, 92093
- Reclutamiento
- University of California at San Diego
-
Los Angeles, California, Estados Unidos, 90048
- Reclutamiento
- Cedars Sinai Medical Center
-
Los Angeles, California, Estados Unidos, 90095
- Reclutamiento
- Ronald Reagan UCLA Medical Center
-
San Francisco, California, Estados Unidos, 94121
- Reclutamiento
- San Francisco VA Medical Center
-
-
Colorado
-
Aurora, Colorado, Estados Unidos, 80045
- Reclutamiento
- University of Colorado Cancer Center
-
Aurora, Colorado, Estados Unidos, 80012
- Reclutamiento
- Rocky Mountain Cancer Centers
-
Lakewood, Colorado, Estados Unidos, 80228
- Reclutamiento
- Colorado Clinical Research
-
-
Connecticut
-
Hartford, Connecticut, Estados Unidos, 06102
- Reclutamiento
- Hartford Hospital
-
-
District of Columbia
-
Washington D.C., District of Columbia, Estados Unidos, 20016
- Reclutamiento
- Johns Hopkins Office of Capital Region Research - Sibley Memorial Hospital
-
-
Florida
-
Bay Pines, Florida, Estados Unidos, 33744
- Reclutamiento
- Bay Pines VA Healthcare System
-
Fort Myers, Florida, Estados Unidos, 33901
- Reclutamiento
- Florida Cancer Specialists & Research Institute
-
Tampa, Florida, Estados Unidos, 33612
- Reclutamiento
- Moffitt Cancer Center
-
-
Iowa
-
Iowa City, Iowa, Estados Unidos, 52242
- Reclutamiento
- University of Iowa Hospital and Clinics
-
Waukee, Iowa, Estados Unidos, 50263
- Reclutamiento
- Mission Cancer Blood
-
-
Louisiana
-
Metairie, Louisiana, Estados Unidos, 70006
- Reclutamiento
- East Jefferson General Hospital
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21287
- Reclutamiento
- Johns Hopkins University
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02115
- Reclutamiento
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- Reclutamiento
- University of Michigan Health System
-
Detroit, Michigan, Estados Unidos, 48202
- Reclutamiento
- Henry Ford Cancer Detroit
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- Reclutamiento
- University Of Minnesota Medical Center
-
-
Nebraska
-
Omaha, Nebraska, Estados Unidos, 68130
- Terminado
- XCancer Omaha / Urology Cancer Center
-
-
New York
-
Brooklyn, New York, Estados Unidos, 11220
- Reclutamiento
- NYU Langone Hospitals
-
Mineola, New York, Estados Unidos, 11501
- Reclutamiento
- NYU Langone Hospital Long Island
-
New York, New York, Estados Unidos, 10032
- Reclutamiento
- Columbia University Medical Center
-
New York, New York, Estados Unidos, 10016
- Reclutamiento
- NYU Langone Health Laura and Isaac Perlmutter Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Estados Unidos, 28204
- Reclutamiento
- Levine Cancer Institute
-
Winston-Salem, North Carolina, Estados Unidos, 27157
- Reclutamiento
- Atrium Health Wake Forest Baptist Comprehensive Cancer Center
-
-
Ohio
-
Cincinnati, Ohio, Estados Unidos, 45219
- Reclutamiento
- University of Cincinnati
-
Cleveland, Ohio, Estados Unidos, 44106
- Reclutamiento
- University Hospital of Cleveland
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- VA Portland Health Care System
-
Portland, Oregon, Estados Unidos, 97227
- Terminado
- Compass Oncology
-
Portland, Oregon, Estados Unidos, 97239
- Reclutamiento
- Oregon Health And Science University
-
Springfield, Oregon, Estados Unidos, 97477
- Reclutamiento
- Oregon Urology Institute
-
-
Pennsylvania
-
Bala-Cynwyd, Pennsylvania, Estados Unidos, 19004
- Reclutamiento
- MidLantic Urology
-
Lancaster, Pennsylvania, Estados Unidos, 17601
- Reclutamiento
- Keystone Urology Specialists
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- Reclutamiento
- Penn Medicine Abramson Cancer Center
-
Pittsburgh, Pennsylvania, Estados Unidos, 15232
- Reclutamiento
- UPMC Cancer Centers
-
-
South Carolina
-
Charleston, South Carolina, Estados Unidos, 29401
- Reclutamiento
- Ralph H Johnson Veterans Hospital
-
Greer, South Carolina, Estados Unidos, 29650
- Reclutamiento
- Gibbs Cancer Center and Research Institute Pelham
-
Myrtle Beach, South Carolina, Estados Unidos, 29572
- Reclutamiento
- Carolina Urologic Research Center
-
Spartanburg, South Carolina, Estados Unidos, 29303
- Reclutamiento
- Gibbs Cancer Center
-
-
Tennessee
-
Chattanooga, Tennessee, Estados Unidos, 37404
- Reclutamiento
- Tennessee Oncology - Chattanooga
-
Nashville, Tennessee, Estados Unidos, 37203
- Reclutamiento
- Tennessee Oncology Nashville
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- Reclutamiento
- UT Southwestern Medical Center
-
Dallas, Texas, Estados Unidos, 75231
- Terminado
- Urology Clinics of North Texas
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- MD Anderson Cancer Center
-
Houston, Texas, Estados Unidos, 77030
- Reclutamiento
- Michael E DeBakey VA Medical Center
-
Wichita Falls, Texas, Estados Unidos, 76310
- Reclutamiento
- Texas Oncology West Texas
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84106
- Reclutamiento
- Utah Cancer Specialists
-
-
Virginia
-
Fairfax, Virginia, Estados Unidos, 22031
- Reclutamiento
- Virginia Cancer Specialists
-
Norfolk, Virginia, Estados Unidos, 23502
- Reclutamiento
- Virginia Oncology Associates
-
Roanoke, Virginia, Estados Unidos, 24014
- Reclutamiento
- Blue Ridge Cancer Care
-
-
Washington
-
Seattle, Washington, Estados Unidos, 98195
- Reclutamiento
- University of Washington
-
Seattle, Washington, Estados Unidos, 98109
- Reclutamiento
- Fred Hutchinson Cancer Research Center
-
Seattle, Washington, Estados Unidos, 98108
- Reclutamiento
- VA Puget Sound Healthcare System
-
-
-
-
-
Bordeaux, Francia, 33000
- Reclutamiento
- Institut Bergonie
-
Brest, Francia, 29200
- Reclutamiento
- CHRU Brest - Hopital Morvan
-
Dijon, Francia, 21000
- Reclutamiento
- Centre Georges Francois Leclerc
-
Lille, Francia, 59000
- Reclutamiento
- Centre Oscar Lambret
-
Lyon, Francia, 69008
- Reclutamiento
- Centre Leon Berard
-
Paris, Francia, 75014
- Reclutamiento
- Hopital Saint Joseph
-
Pierre-Bénite, Francia, 69495
- Reclutamiento
- CHU Lyon Sud
-
Saint-Herblain, Francia, 44805
- Reclutamiento
- I.C.O. Rene Gauducheau
-
Strasbourg, Francia, 672098
- Reclutamiento
- Hopitaux universitaires de Strasbourg
-
Vandœuvre-lès-Nancy, Francia, 54519
- Reclutamiento
- Institut de Cancerologie de Lorraine
-
Villejuif, Francia, 94800
- Reclutamiento
- Gustave Roussy
-
-
-
-
-
Foggia, Italia, 71122
- Reclutamiento
- Ospedali Riuniti Foggia
-
Milan, Italia, 20133
- Reclutamiento
- Fondazione IRCCS Istituto Nazionale dei Tumori
-
Naples, Italia, 80131
- Reclutamiento
- Azienda Ospedaliera Universitaria Federico II
-
Padova, Italia, 35128
- Reclutamiento
- IOV IRCCS Padova
-
Palermo, Italia, 90127
- Reclutamiento
- Azienda Di Rilievo Nazionale E Di Alta Specializzazione
-
Roma, Italia, 00168
- Reclutamiento
- Fondazione Policlinico Universitario A Gemelli IRCCS
-
Rozzano, Italia, 20089
- Reclutamiento
- Istituto Clinico Humanitas
-
Torino, Italia, 10126
- Reclutamiento
- A.O.U. Citta della Salute e della Scienza di Torino - Presidio Molinette
-
-
-
-
-
Bunkyō City, Japón, 113 8519
- Reclutamiento
- Institute of Science Tokyo Hospital
-
Fukuoka, Japón, 812 8582
- Reclutamiento
- Kyushu University Hospital
-
Gifu, Japón, 501-1194
- Reclutamiento
- Gifu University Hospital
-
Hidaka, Japón, 350 1298
- Reclutamiento
- Saitama Medical University International Medical Center
-
Kanazawa, Japón, 920 8641
- Reclutamiento
- Kanazawa University Hospital
-
Kashiwa, Japón, 277 8577
- Reclutamiento
- National Cancer Center Hospital East
-
Kobe, Japón, 650 0017
- Reclutamiento
- Kobe University Hospital
-
Matsuyama, Japón, 791-0280
- Reclutamiento
- National Hospital Organization Shikoku Cancer Center
-
Meguro Ku, Japón, 152 8902
- Reclutamiento
- National Hospital Organization Tokyo Medical Center
-
Sakura, Japón, 285-8741
- Reclutamiento
- Toho University Sakura Medical Center
-
Sapporo, Japón, 060 8648
- Reclutamiento
- Hokkaido University Hospital
-
Yokohama, Japón, 232 0024
- Reclutamiento
- Yokohama City University Medical Center
-
Yokohama, Japón, 236 0004
- Reclutamiento
- Yokohama City University Hospital
-
Yokosuka, Japón, 238 8558
- Reclutamiento
- Yokosuka Kyosai Hospital
-
-
-
-
-
Delft, Países Bajos, 2625 AD
- Reclutamiento
- Reinier de Graaf Gasthuis
-
Groningen, Países Bajos, 9728NT
- Terminado
- Martini Ziekenhuis
-
Hilversum, Países Bajos, 1212 VG
- Reclutamiento
- Tergooi
-
Hoofddorp, Países Bajos, 2134 TM
- Reclutamiento
- Spaarne Gasthuis
-
Maastricht, Países Bajos, 6229 HX
- Reclutamiento
- Maastricht UMC
-
Nijmegen, Países Bajos, 6532 SZ
- Reclutamiento
- Canisius-Wilhelmina ZH
-
Rotterdam, Países Bajos, 3015 GD
- Reclutamiento
- Erasmus MC
-
Zwolle, Países Bajos, 8025 AB
- Reclutamiento
- Isala Kliniek
-
-
-
-
-
Bialystok, Polonia, 15 276
- Reclutamiento
- Uniwersytecki Szpital Kliniczny w Bialymstoku
-
Bydgoszcz, Polonia, 85 048
- Reclutamiento
- IN VIVO Sp. z o.o
-
Koszalin, Polonia, 75-581
- Reclutamiento
- Szpital Wojewodzki im Mikolaja Kopernika w Koszalinie
-
Warsaw, Polonia, 02 781
- Reclutamiento
- Narodowy Instytut Onkologii im Marii Sklodowskiej Curie Panstwowy Instytut Badawczy
-
Warsaw, Polonia, 04 073
- Reclutamiento
- Szpital Grochowski Im Dr Med Rafala Masztaka Sp Z O O
-
-
-
-
-
Beijing, Porcelana, 100034
- Reclutamiento
- Peking University First Hospital
-
Changchun, Porcelana, 130021
- Reclutamiento
- The First Bethune Hospital of Jilin University
-
Chengdu, Porcelana, 610041
- Reclutamiento
- West China Hospital of Sichuan University
-
Chengdu, Porcelana, 500643
- Reclutamiento
- The Third People's Hospital of Chengdu
-
Chongqing, Porcelana, 400030
- Reclutamiento
- Chongqing University Cancer Hospital
-
Guangzhou, Porcelana, 510060
- Reclutamiento
- Sun Yat Sen University Cancer Center
-
Nanjing, Porcelana, 210008
- Reclutamiento
- Nanjing Drum Tower Hospital
-
Nanning, Porcelana, 530021
- Reclutamiento
- The First Affiliated Hospital of Guangxi Medical University
-
Nantong, Porcelana, 226300
- Reclutamiento
- Nantong Tumor Hospital
-
Ningbo, Porcelana, 315010
- Reclutamiento
- The First Affiliated Hospital of Ningbo University
-
Shanghai, Porcelana, 200032
- Reclutamiento
- Fudan University Shanghai Cancer Center
-
Tianjin, Porcelana, 300211
- Reclutamiento
- The Second Hospital Of Tianjin Medical University
-
Wenzhou, Porcelana, 325000
- Reclutamiento
- The First Affiliated Hospital of Wenzhou Medical University
-
Wuhan, Porcelana, 430071
- Reclutamiento
- Zhongnan Hospital Wu Han University
-
Xi'an, Porcelana, 710061
- Reclutamiento
- The First Affiliated Hospital of Xian Jiaotong University
-
-
-
-
-
Rio Piedras, Puerto Rico, 00935
- Reclutamiento
- Pan American Center for Oncology Trials LLC
-
San Juan, Puerto Rico, 00917
- Reclutamiento
- Puerto Rico Medical Research Center
-
-
-
-
-
Birmingham, Reino Unido, B15 2TH
- Reclutamiento
- University Hospitals Birmingham NHS Foundation Trust
-
London, Reino Unido, WC1E 6BT
- Reclutamiento
- University College London Hospitals
-
Manchester, Reino Unido, M20 4BX
- Reclutamiento
- The Christie NHS Foundation Trust Christie Hospital
-
Sutton, Reino Unido, SM2 5PT
- Reclutamiento
- Royal Marsden Hospital (Sutton)
-
-
-
-
-
Kaohsiung City, Taiwán, 833
- Reclutamiento
- Chang Gung Memorial Hospital
-
Taichung, Taiwán, 40705
- Reclutamiento
- Taichung Veterans General Hospital
-
Taichung, Taiwán, 435
- Reclutamiento
- Tungs' Taichung MetroHarbor Hospital
-
Taipei, Taiwán, 100
- Reclutamiento
- National Taiwan University Hospital
-
Taipei, Taiwán, 112
- Reclutamiento
- Taipei Veterans General Hospital
-
Taoyuan, Taiwán, 333
- Reclutamiento
- Linkou Chang Gung Memorial Hospital
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Descripción
Inclusion Criteria
- Histologically confirmed adenocarcinoma of the prostate
- Metastatic castration-resistant prostate cancer (mCRPC): Disease that is metastatic either to bone, any lymph node, or both without clear evidence of other metastatic sites at the time of screening by conventional imaging with computed tomography (CT) or magnetic resonance imaging (MRI) (chest, abdomen, and pelvis) and 99m^Tc bone scan. Visceral disease is not allowed
- PSA greater than or equal to (≥) 2 nanogram per milliliter (ng/mL) at screening
- In the opinion of the investigator, the next best treatment option is a clinical trial
- Participants are required to have had all life-prolonging therapies for which they are clinically eligible in the opinion of the investigator and to which they have access. Prior therapies could have been given in any disease setting (not limited to mCRPC). In particular, prior treatment specifications include receipt of the following:
Androgen-receptor pathway inhibitor (ARPI): Must have progressed on at least 1 ARPI and unlikely to benefit from retreatment with another ARPI
Taxanes: Required to have received at least 2 previous taxane-based regimens. If a participant has received only 1 taxane regimen, the participant is eligible if:
- Cabazitaxel is not available
- The participant's physician deems the participant unsuitable to receive a second taxane regimen due to toxicity risk or prior intolerance Note: a taxane-based regimen consists of at least 2 cycles of a taxane (either as a single agent or in combination with other therapies) administered within the same 2-month period
Radioligand therapy: Required to have been previously treated with at least 1 dose of Prostate-specific membrane antigen (PSMA)-targeted lutetium radioligand therapy (eg, lutetium Lu-177 vipivotide tetraxetan), unless one of the following applies:
- PSMA-targeted lutetium radioligand therapy is unavailable, not accessible, or not clinically indicated.
- The participant's physician deems the participant unsuitable to receive PSMA-targeted lutetium radioligand therapy.
Polyadenosine diphosphate-ribose polymerase inhibitors (PARPi): Required to have been previously treated with PARPi, if the participant has a known germline or somatic BRCA mutation and treatment is available
- Prior orchiectomy or medical castration (receiving ongoing ADT with a GnRH analog [agonist or antagonist]) prior to the first dose of study treatment and must continue this therapy throughout the treatment phase
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2
- Participants are eligible if they have the following values:
A) eGFR ≥ 40 milliliters per minute (mL/min) B) Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) less than or equal to (≤) 3 times the Upper Limit of Normal (ULN) C) Total bilirubin <1.5 times ULN D) Absolute neutrophil count (ANC) ≥ 1.0x10^9/per liter (L) E) Hemoglobin ≥ 8.0 grams per deciliter (g/dL) F) Platelet count ≥ 75x10^9/L
Exclusion Criteria
- Venous thromboembolic events within 1 month prior to the first dose of study treatment; uncomplicated (Grade ≤ 2) deep vein thrombosis is not exclusionary
- Active autoimmune disease within the past 12 months that requires systemic immunosuppressive medications (eg, chronic corticosteroid, methotrexate, or tacrolimus)
- Participants with Grade 1 or higher fever (≥38ºC) or active infection requiring systemic treatment within 7 days prior to randomization are ineligible. Participants must be afebrile (<38ºC) at the time of study treatment dosing unless approved by medical monitor
- Clinically significant pulmonary compromise, particularly a requirement for supplemental oxygen use (>2 liters per minute (L/min) by nasal cannula) to maintain adequate oxygenation
- Prior or concurrent second malignancy (other than the disease under study) for which natural history or treatment could likely interfere with any study endpoints of safety or the efficacy of the study treatment(s)
- Any of the following within 6 months prior to first dose of study treatment:
A) Myocardial infarction B) Severe or unstable angina C) Clinically significant ventricular arrhythmias D) Congestive heart failure (New York Heart Association class II to IV) E) Transient ischemic attack F) Cerebrovascular accident
- Prior treatment with any CD3-directed therapy
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Propósito principal: Tratamiento
- Asignación: Aleatorizado
- Modelo Intervencionista: Asignación paralela
- Enmascaramiento: Doble
Armas e Intervenciones
Grupo de participantes/brazo |
Intervención / Tratamiento |
|---|---|
|
Experimental: Part 1: Pasritamig+Best Supportive Care (BSC)
Participants in Part 1 will receive 2 step-up doses of pasritamig intravenously (IV) followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Otros nombres:
BSC will be administered at the discretion of the treating physician. |
|
Comparador de placebos: Part 1: Placebo+BSC
Participants in Part 1 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
|
Experimental: Part 2: Pasritamig+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Otros nombres:
BSC will be administered at the discretion of the treating physician. |
|
Experimental: Part 2: Pasritamig+JNJ-87189401+BSC
Participants in Part 2 will receive 2 step-up doses of pasritamig IV followed by the target dose. JNJ-87189401 will be administered with the first target dose of pasritamig. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
Pasritamig will be administrated through IV infusion.
Otros nombres:
BSC will be administered at the discretion of the treating physician. JNJ-87189401 will be administered. |
|
Comparador de placebos: Part 2: Placebo +BSC
Participants in Part 2 will receive 2 step-up doses of placebo IV followed by the target dose. Participants will receive study treatment until confirmed progressive disease, death, intolerable toxicity, withdrawal of consent, or end of the study, whichever occurs first. All participants may receive BSC (defined as palliative external beam radiation, low dose steroids, pain medication, bone sparing agents, and needed palliative procedures) at the discretion of the physician. |
BSC will be administered at the discretion of the treating physician. Placebo will be administrated through IV infusion. |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Overall Survival (OS)
Periodo de tiempo: Up to 2 years and 8 months
|
OS is defined as the time from randomization to date of death due to any cause. |
Up to 2 years and 8 months
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
Radiographic Progression-free Survival (rPFS)
Periodo de tiempo: Up to 2 years and 8 months
|
rPFS assessed by investigator defined as the time from the date of randomization until the date of radiographic disease progression (based on response evaluation criteria in solid tumors [RECIST] version (v) 1.1 and prostate cancer working group 3 [PCWG3] criteria) or death, whichever comes first. |
Up to 2 years and 8 months
|
|
Time to Symptomatic Progression
Periodo de tiempo: Up to 2 years and 8 months
|
Time to symptomatic progression is defined as time from the date of randomization to the date of any of the following (whichever occurs first): (a) the use of external beam radiation therapy to relieve cancer-related symptoms; (b) the need for tumor-related orthopedic surgical intervention; (c) other cancer-related procedures; (d) cancer-related morbid events; (e) initiation of a new systemic anti-cancer therapy because of cancer symptoms. |
Up to 2 years and 8 months
|
|
Time to Skeletal-Related Event
Periodo de tiempo: Up to 2 years and 8 months
|
Time to skeletal-related event is defined as the time from the date of randomization to the date of first occurrence of any of the following (whichever occurs first): (a) the use of external beam radiation for skeletal or pelvic symptoms; b) the need for tumor-related orthopedic surgical intervention; (c) the occurrence of new bone fractures (cancer-related); (d) the occurrence of tumor-related spinal cord compression. |
Up to 2 years and 8 months
|
|
Progression-Free Survival (PFS)
Periodo de tiempo: Up to 2 years and 8 months
|
PFS is defined as the date of randomization to the date of first evidence of radiographic progression, clinical progression, or death from any cause, whichever occurs first. |
Up to 2 years and 8 months
|
|
Time to Prostate Specific Antigen (PSA) Progression
Periodo de tiempo: Up to 2 years and 8 months
|
Time to PSA progression, defined as the time from randomization to the first date of documented PSA progression per PCWG3 criteria. PSA progression is defined as: after a decline from baseline, PSA increases >= 25 percentage (%) and >= 2 nanograms per milliliter (ng/mL) above the nadir, confirmed by a second value >= 3 weeks later (that is, a confirmed rising trend), or If there is no decline from baseline, PSA increases >= 25 % and >= 2 ng/mL from baseline after 12 weeks. |
Up to 2 years and 8 months
|
|
Time to Pain Progression (TTPP) as Assessed by the Brief Pain Inventory-Short Form (BPI-SF) Item 3 Worst Pain in 24 Hours
Periodo de tiempo: Up to 2 years and 8 months
|
TTPP is defined as the time from the date of randomization to the date of the first observation of pain progression. Pain progression is defined as an increase of at least 2 points from baseline in the BPI-SF worst pain intensity (item 3) observed at 2 consecutive evaluations >= 3 weeks apart. BPI-SF is an 11-item questionnaire, designed to assess severity and impact of pain on daily functions. Total score range from 0 to 10 with 0 representing "no pain" and 10 representing" pain as bad as you can imagine". |
Up to 2 years and 8 months
|
|
Time to Deterioration in Fatigue as Assessed by the European Organisation For Research And Treatment of Cancer Quality of Life Questionnaire-Core-30 (EORTC QLQ-C30) Fatigue Scale Score
Periodo de tiempo: Up to 2 years and 8 months
|
Time to deterioration is defined as the time from randomization to the date of the first observation of deterioration in Fatigue. Deterioration in Fatigue is defined as an increase of 10 points on the EORTC QLQ-C30 FA scale observed at 2 consecutive evaluations >= 3 weeks apart. The EORTC QLQ-C30 is a widely used tool for assessing the quality of life of cancer patients in clinical trials. Responses to items 1-28 are rated on a 4-point Likert response scale ranging from 1 "Not at all" to 4 "Very much". Two global health status items are rated on a 7-point numeric rating scale from 1 "Very Poor" to 7 "Excellent". Each subscale of the EORTC QLQ-C30 is scored on a range from 0 to 100. Higher scores indicate worse symptoms or problems. |
Up to 2 years and 8 months
|
|
Number of Participants with Adverse Events (AEs)
Periodo de tiempo: Up to 2 years and 8 months
|
An AE is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/biological agent under study. |
Up to 2 years and 8 months
|
|
Number of Participants with Abnormalities in Clinical Laboratory Assessments
Periodo de tiempo: Up to 2 years and 8 months
|
Participants with abnormalities in clinical laboratory parameters (hematology, clinical chemistry etc.) will be assessed. |
Up to 2 years and 8 months
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Director de estudio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
- Enfermedades urogenitales
- Enfermedades Genitales
- Neoplasias Genitales Masculinas
- Neoplasias urogenitales
- Neoplasias por sitio
- Neoplasias
- Enfermedades Genitales Masculinas
- Enfermedades prostáticas
- Enfermedades urogenitales masculinas
- Neoplasias prostáticas
- Neoplasias prostáticas resistentes a la castración
Otros números de identificación del estudio
- 78278343PCR3001
- 2025-520927-26-00 (Identificador de registro: EUCT number)
- 2025 (Subvención/contrato del NIH de EE. UU.)
Plan de datos de participantes individuales (IPD)
¿Planea compartir datos de participantes individuales (IPD)?
Descripción del plan IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .